At the close of the previous year, Manina Medtech, a spin-off from the Vall d’Hebron Institute of Research (VHIR), secured €1.75M in funding to support the development and clinical trials of their new medical device, SEEDCHRONY. This device is positioned to advance In Vitro Fertilization (IVF) outcomes by improving embryo implantation processes. The funding round included significant investments from a consortium of business angels, led by Medex Partners, and was further supported by the Ministerio de Ciencia e Innovación through its national program for scientific research and transfer.
Manina Medtech focuses on developing SEEDCHRONY to increase the success rate of IVF treatments. The device utilizes a sensor integrated into the transfer catheter to detect specific biomarkers, combined with artificial intelligence technology, to provide an instantaneous assessment of the uterine environment for embryo implantation.
The financial injection is set to accelerate the company’s research and development. The funds will be allocated towards extensive clinical research, validation of SEEDCHRONY’s effectiveness, and the enhancement of its technological infrastructure. Moreover, the funding will facilitate the expansion of the company’s team, incorporating additional expertise in IT, regulatory legislation, and clinical research to ensure the device meets all necessary standards and regulations.
